Rigel Pharma (RIGL) Misses Q3 EPS by 1c

November 1, 2016 5:06 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.97 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment